Rituximab treatment results in impaired secondary humoral immune responsiveness

Lizet E. van der Kolk; Joke W. Baars; Martin H. Prins; Marinus H. J. van Oers

Rituximab treatment results in impaired secondary humoral immune responsiveness

Lizet E. van der Kolk, Joke W. Baars, Martin H. Prins, Marinus H. J. van Oers

Clinical Haematology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

255 Citations (Scopus)

Abstract

In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab

Original language	English
Pages (from-to)	2257-2259
Journal	Blood
Volume	100
Issue number	6
Publication status	Published - 2002

Cite this

@article{597cac0ed57947519c30625a5171dcfe,

title = "Rituximab treatment results in impaired secondary humoral immune responsiveness",

abstract = "In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab",

author = "{van der Kolk}, {Lizet E.} and Baars, {Joke W.} and Prins, {Martin H.} and {van Oers}, {Marinus H. J.}",

year = "2002",

language = "English",

volume = "100",

pages = "2257--2259",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - Rituximab treatment results in impaired secondary humoral immune responsiveness

AU - van der Kolk, Lizet E.

AU - Baars, Joke W.

AU - Prins, Martin H.

AU - van Oers, Marinus H. J.

PY - 2002

Y1 - 2002

N2 - In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab

AB - In lymphoma patients, treatment with chimeric CD20 monoclonal antibodies (rituximab) results in a depletion of normal and malignant B cells, persisting for 6 to 9 months. This B-cell depletion leads neither to a decrease in immunoglobulin levels nor an increase in the number of infectious complications. However, the effect of rituximab treatment on the immune responsiveness is unknown. In 11 patients with relapsed, low-grade lymphoma, we investigated the effect of rituximab treatment on the humoral immune response to primary antigens and 2 recall antigens. After rituximab treatment, the humoral immune response to the recall antigens was significantly decreased when compared with the response before treatment. Already before rituximab treatment, none of these patients was able to mount a response to the primary antigens. These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab

M3 - Article

C2 - 12200395

SN - 0006-4971

VL - 100

SP - 2257

EP - 2259

JO - Blood

JF - Blood

IS - 6

ER -